PTCL
4
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
375%
Small Molecule
125%
+ 1 programs with unclassified modality
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Yingli PharmaYY-20394 treatment
OtsukaPembrolizumab
Boehringer IngelheimVolasertib
Clinical Trials (3)
Total enrollment: 127 patients across 3 trials
A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Start: Apr 2021Est. completion: Jun 202390 patients
Phase 2Unknown
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Start: Feb 2022Est. completion: May 202637 patients
Phase 1Active Not Recruiting
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
Start: Nov 2016Est. completion: Nov 20160
Phase 1Withdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (75% of programs)
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.